Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
Marine Bruand, David Barras, Marco Mina, Eleonora Ghisoni, Matteo Morotti, Evripidis Lanitis, Noémie Fahr, Mathieu Desbuisson, Alizée J Grimm, Hualing Zhang, Chloé Chong, Julien Dagher, Sora Chee, Theodora Tsianou, Julien Dorier, Brian J. Stevenson, Christian Iseli, Catherine Ronet, Sara Bobisse, Raphaël Genolet, Josephine Walton, Michal Bassani‐Sternberg, Lana E. Kandalaft, Bing Ren, Iain A. McNeish, Elizabeth M. Swisher, Alexandre Harari, Mauro Delorenzi, Giovanni Ciriello, Melita Irving, Sylvie Rusakiewicz, Periklis Foukas, Fabio Martinon, Denarda Dangaj Laniti, George Coukos
Abstract
ovarian tumors in vivo, offering rational combinatorial therapies for HRD cancers.
Topics & Concepts
Cancer researchInflammationBiologyImmune systemChemokineImmune checkpointImmunotherapyImmunologyinterferon and immune responsesVirus-based gene therapy researchCytomegalovirus and herpesvirus research